Innovative drugs "go to sea", increase holdings in medical beauty equipment companies...... The pharmaceutical company has been making a lot of moves recently

【Pharmaceutical Network Enterprise News】In recent years, affected by the resonance of policies, industries, talents, capital, etc.
, domestic innovative drug enterprises have continuously increased their R&D investment, domestic innovative drug boom has risen, and more and more powerful pharmaceutical companies have "gone to sea" innovative drugs in the case of fierce competition on the track, so that the world can hear the voice of
domestic innovative drugs 。 Recently, Fosun Pharma announced that the Company and Kefipin Pharma have signed a licensing agreement whereby the two parties will jointly develop and commercialize Caprazon hydrochloride exclusively by Fosun Pharma Industry, including all available indications for oral preparations and general injections of Keprasin hydrochloride, and the two parties will cooperate
globally.
It is understood that Keprasen hydrochloride is the first potassium ion competitive acid blocker (P-CAB) independently developed in China, which is suitable for the treatment of duodenal ulcer, reflux esophagitis and Helicobacter pylori infection
.
The drug can overcome many defects
such as slow onset of action and unstable acid suppression of proton pump inhibitors (PPI) drugs that are widely used in clinical practice.
According to the license agreement, in China (excluding Hong Kong, Macao and Taiwan), as the holder of the marketing authorization for the cooperative products, Fosun Pharma Industry enjoys exclusive commercialization rights, including marketing and distribution
.
Outside of China, Fosun Pharma, as the holder of the marketing authorization for the cooperative products, enjoys exclusive product rights, including but not limited to clinical research, registration, commercialization, sub-licensing, etc
.
According to the data, Fosun Pharma is a global pharmaceutical and health industry group rooted in China and driven by innovation, directly operating businesses including pharmaceuticals, medical devices and medical diagnosis, medical and health services, and covering the pharmaceutical business field
through its participation in Sinopharm Holdings.
For Fosun Pharma, this cooperation can help pharmaceutical companies strengthen the upstream of innovation and R&D, and help realize mutual empowerment between the two sides, further expand the market, and achieve win-win
cooperation.
It is understood that in recent years, Fosun Pharma has continued to
move.
In addition to the innovative drug "going to sea", the company has also increased its holdings in the medical beauty device company Furui Medical Technology, increasing its layout
in the field of medical devices.
On the evening of September 20, Furui Medical Technology announced that the Company was informed by Nengyue, a wholly-owned subsidiary of Fosun Pharma, that Nengyue and its subsidiaries (other than the Company) plan to purchase no more than 1% of the total number of issued shares of the Company during the six-month period from the date of the announcement
.
On 20 September 2022, Nengyue purchased 138,400 shares at an average price of HK$7.
5745 per share
.
As at 20 September 2022, Fosun Pharma, the controlling shareholder of the Company, had an interest in a total of 331,732,800 shares through its wholly-owned subsidiaries, equivalent to approximately 71.
16%
of the issued share capital of the Company.
Owned by Fosun Pharma, Furui Medical Technology is a core member of Fosun System, and its main businesses include medical aesthetic equipment, injection filling, cosmetic dentistry, personal care, etc
.
The analysis believes that the domestic medical device industry is developing rapidly, of which the medical aesthetic device market is huge
.
According to data, the market size of China's medical aesthetic devices will exceed 60 billion yuan
in 2022.
Fosun Pharma chose to increase its stake in "Furui Medical Technology" this time, or plan to develop
the center into the medical device business.
Fosun Pharma's 2021 financial report shows that during the reporting period, it achieved operating income of 39.
005 billion yuan, an increase of 28.
7% year-on-year; Net profit attributable to listed companies was 4.
735 billion yuan, an increase of 29.
28% year-on-year; The non-net profit attributable to listed companies was 3.
277 billion yuan, an increase of 20.
6%
year-on-year.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.